Briefing at Congress: The Changing Face of HIV/AIDS in America

Briefing: 

 The Changing Face of HIV/ AIDS in America

September 18, 2013 

Briefing: 9:30-10:30 a.m.

Reception: 10:30-11 :30 a.m.

US Congress Capitol Visitors Center, Room SVC 212

Hosted by:

AIDS Community Research Initiative of America (ACRIA) 

Services and Advocacy for GLBT Elders (SAGE) 

National Hispanic Council on Aging

Once a Month HIV Medications - Cost Effectiveness

Long-acting antiretroviral (ARV) formulations, now in clinical development, could prolong survival in people with HIV, according to results of a modeling study [1]. But the benefit may hold true only in people with barriers to good adherence. Although long-acting antiretrovirals may not be cheap, the researchers determined they could be "a good value" when used mainly for poorly adherent patients.

ID Week: "The Clinical Role and Cost-effectiveness of Long-acting Antiretroviral Formulations" - Long-Acting ARV Formulations Could Improve Survival in People With Poor Adherence